Peptide-Functionalized Nanomaterials for the Efficient Isolation of HER2-Positive Circulating Tumor Cells

Peng, Jiaxi; Zhao, Qiong; Zheng, Wangshu; Li, Wenzhe; Li, Ping; Zhu, Ling; Liu, Xiaoran; Shao, Bin; Li, Huiping; Wang, Chen; Yang, Yanlian

doi:10.1021/acsami.7b03905

Cited by 46 publications

(38 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, improvements have been made on the probe that is functionalized on the MNPs, as was reported by Bai et al and Peng et al who modified the MNPs with de novo designed peptides that had high affinity to the marker membrane proteins on CTCs (e.g., EpCAM and HER2) ( Figure a) . The peptide‐functionalized MNPs exhibited high capture efficiency for the CTCs in breast, prostate, and liver cancers, reaching a capture rate of above 90% for CTCs or 68% for HER2 positive CTCs, much higher than the one with antibody‐functionalized MNPs showing the potential of high affinity peptides as probes for improving the detection sensitivity. Slow magnetic response and high loss rate have been the problems for MNPs due to the small size of the nanoparticles.…”

Section: Advances and Challenges Of Nanotechnology‐based Liquid Biopsymentioning

confidence: 97%

“…Most liquid biopsy strategies include the enrichment of targets from the body fluids such as the peripheral blood and the subsequent characterization and analysis of the isolated targets. Current isolation and enrichment of CTCs and EVs are mainly based on two approaches: the separation of CTCs and EVs based on their characteristic physical properties (e.g., size, deformability, and adhesion) and the immunoaffinity‐based enrichment, usually in virtue of molecular probes such as antibodies, peptides, and aptamers …”

Section: Advances and Challenges Of Nanotechnology‐based Liquid Biopsymentioning

confidence: 99%

“…They used magnetic nanoparticles (MNPs) functionalized with this EpCAM‐targeting peptide to capture CTCs and reached a capture rate of above 90% . Several years later, the same group reported a de novo designed peptide with high affinity to HER2, and used the peptide‐functionalized MNPs to capture HER2‐positive CTCs in breast cancer, achieving a capture efficiency of 68.56–79.26% . Aptamers are single‐stranded DNA or RNA oligonucleotides that fold into unique 3D conformations.…”

Section: Advances and Challenges Of Nanotechnology‐based Liquid Biopsymentioning

confidence: 99%

See 2 more Smart Citations

Emerging Nanotechnologies for Liquid Biopsy: The Detection of Circulating Tumor Cells and Extracellular Vesicles

Li¹,

Wang²,

Zhao³

et al. 2018

Advanced Materials

Self Cite

View full text Add to dashboard Cite

Liquid biopsy enables noninvasive and dynamic analysis of molecular or cellular biomarkers, and therefore holds great potential for the diagnosis, prognosis, monitoring of disease progress and treatment efficacy, understanding of disease mechanisms, and identification of therapeutic targets for drug development. In this review, the recent progress in nanomaterials, nanostructures, nanodevices, and nanosensors for liquid biopsy is summarized, with a focus on the detection and molecular characterization of circulating tumor cells (CTCs) and extracellular vesicles (EVs). The developments and advances of nanomaterials and nanostructures in enhancing the sensitivity, specificity, and purity for the detection of CTCs and EVs are discussed. Sensing techniques for signal transduction and amplification as well as visualization strategies are also discussed. New technologies for the reversible release of the isolated CTCs and EVs and for single‐CTC/EV analysis are summarized. Emerging microfluidic platforms for the integral on‐chip isolation, detection, and molecular analysis are also included. The opportunities, challenges, and prospects of these innovative materials and technologies, especially with regard to their feasibility in clinical applications, are discussed. The applications of nanotechnology‐based liquid biopsy will bring new insight into the clinical practice in monitoring and treatment of tumor and other significant diseases.

show abstract

Section: Advances and Challenges Of Nanotechnology‐based Liquid Biopsymentioning

confidence: 97%

Section: Advances and Challenges Of Nanotechnology‐based Liquid Biopsymentioning

confidence: 99%

Section: Advances and Challenges Of Nanotechnology‐based Liquid Biopsymentioning

confidence: 99%

See 1 more Smart Citation

Emerging Nanotechnologies for Liquid Biopsy: The Detection of Circulating Tumor Cells and Extracellular Vesicles

Li¹,

Wang²,

Zhao³

et al. 2018

Advanced Materials

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition, SPNs have been developed into smart anticancer materials through the introduction of activatable linkers that can be cleaved only in the tumor microenvironment or upon light irradiation . Tamoxifen (Tam) is a non‐steroidal triphenylethylene derivative and was the first selective estrogen receptor modulator whereas Herceptin targets HER2 for the treatment of breast cancer . Vivek and co‐workers developed HER2‐targeting poly(vinylpyrrolidone) (PVP)–poly( d , l ‐lactic‐ co ‐glycolic acid) (PLGA) nanoparticular drug delivery system, with the combination of Tam (targeting agent) and Herceptin (enhances the cytoplasmic delivery of post‐endocytosed nanoparticles loaded with Tam) enhancing the therapeutic efficacy toward HER2‐positive metastatic breast cancer cells.…”

Section: Antibody‐conjugated Nanomaterialsmentioning

confidence: 99%

Bio‐Conjugated Advanced Materials for Targeted Disease Theranostics

Kwon

Yan

et al. 2020

Adv Funct Materials

View full text Add to dashboard Cite

Human beings are “machines” that use endogenously produced biomolecules as “components” in signaling and for the maintenance of the body. These biomolecules consist of proteins, nucleic acids, and carbohydrates, which can either be extracted from biological substrates or synthesized by chemical/biochemical methods. These biomolecules have the ability to recognize/interact with other biomolecules that are overexpressed in disease cells. For targeted theranostics, strategies to chemically incorporate these natural biomolecules with advanced materials to treat human diseases by imaging‐guided drug delivery or photodynamic/photothermal therapy are proposed, with improved biocompatibility. Herein, recent research on construction of quantum dots, nanoparticles, and 2D material platforms decorated with antibodies, peptides, nucleic acid aptamers, carbohydrates, and folic acid for targeted diagnosis and treatment are summarized and discussed. In addition, the various strategies required to construct effective functional materials for targeted cancer therapy are highlighted. The hope is that this review can inspire and guide those that are interested in the field of biomedicine to rationally design and develop new target‐based theranostic materials.

show abstract

“…Recognition peptides are other linkers also acknowledged as adequate antibody substitutes for CTCs capture. This is due to their application simplicity and employment in ligand-receptor and protein–protein interactions [129].…”

Section: Circulating Tumor Cellsmentioning

confidence: 99%

Microfluidics for studying metastatic patterns of lung cancer

et al. 2019

View full text Add to dashboard Cite

The incidence of lung cancer continues to rise worldwide. Because the aggressive metastasis of lung cancer cells is the major drawback of successful therapies, the crucial challenge of modern nanomedicine is to develop diagnostic tools to map the molecular mechanisms of metastasis in lung cancer patients. In recent years, microfluidic platforms have been given much attention as tools for novel point-of-care diagnostic, an important aspect being the reconstruction of the body organs and tissues mimicking the in vivo conditions in one simple microdevice. Herein, we present the first comprehensive overview of the microfluidic systems used as innovative tools in the studies of lung cancer metastasis including single cancer cell analysis, endothelial transmigration, distant niches migration and finally neoangiogenesis. The application of the microfluidic systems to study the intercellular crosstalk between lung cancer cells and surrounding tumor microenvironment and the connection with multiple molecular signals coming from the external cellular matrix are discussed. We also focus on recent breakthrough technologies regarding lab-on-chip devices that serve as tools for detecting circulating lung cancer cells. The superiority of microfluidic systems over traditional in vitro cell-based assays with regard to modern nanosafety studies and new cancer drug design and discovery is also addressed. Finally, the current progress and future challenges regarding printable and paper-based microfluidic devices for personalized nanomedicine are summarized. Electronic supplementary material The online version of this article (10.1186/s12951-019-0492-0) contains supplementary material, which is available to authorized users.

show abstract

Peptide-Functionalized Nanomaterials for the Efficient Isolation of HER2-Positive Circulating Tumor Cells

Cited by 46 publications

References 31 publications

Emerging Nanotechnologies for Liquid Biopsy: The Detection of Circulating Tumor Cells and Extracellular Vesicles

Emerging Nanotechnologies for Liquid Biopsy: The Detection of Circulating Tumor Cells and Extracellular Vesicles

Bio‐Conjugated Advanced Materials for Targeted Disease Theranostics

Microfluidics for studying metastatic patterns of lung cancer

Contact Info

Product

Resources

About